Capabilities by Region

Greenhill is active in all major markets with meaningful corporate advisory activity, including in North America, Europe,  Asia, and Australia.

Recent Transactions

23-Jan-23
Pending
$200 million
United Kingdom flag
Target: 

Clinigen Ltd’s Proleukin

United States flag
Acquiror: 
Iovance Biotherapeutics

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

02-Nov-22
Undisclosed
United States flag
Target: 

Medallion Delaware Basin, LLC

United States flag
Acquiror: 
Cardinal Midstream Partners

Advised Medallion Midstream and The Energy & Minerals Group on the sale of Medallion Delaware, a newly-built natural gas gathering & processing system in the heart of the Delaware Basin, to Cardinal Midstream Partners

10-Feb-23
Pending
$415 million
United States flag
Target: 

Gaming Services Division of Global Payments

United States flag
Acquiror: 
Parthenon Capital

Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm

16-Feb-23
Pending
$220 million
U.S.A., U.K. flags
Target: 

Flavor Specialty Ingredients division of IFF

United Kingdom flag
Acquiror: 
Exponent Private Equity

Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market

20-Mar-23
Pending
Undisclosed
Target: 

Clinigen Ltd’s Lamda Laboratories

Germany flag
Acquiror: 
Adragos Pharma

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

Pages

show all